DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for Markets Morning Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

Dear Reader, As per your request, you have been removed from our mailing list for ETtech Unwrapped Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE TUE, JUL 23, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The first round of the Biden administration's Medicare drug price negotiations is nearly finished, with two major deadlines approaching.  President Joe Biden's signature Inflation Reduction Act gave Medicare the power to directly hash out drug prices with manufacturers for the first time in the federal program's nearly six-decade history. That process aims to make expensive medications more affordable for older Americans, but the pharmaceutical industry argues that it is a threat to their revenue, profits and drug innovation.  The government and manufacturers have been in talks since February, when Medicare sent its initial price offer for each of the 10 medications selected almost a year ago. That includes diabetes treatments from Merck, AstraZeneca and Boehringer Ingelhei